These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1707855)

  • 1. Neutralizing antibodies and antigens in AIDS.
    Norley SG; Kurth R
    Infection; 1991; 19 Suppl 2():S83-8. PubMed ID: 1707855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
    Lu Y; Ding J; Chen YH
    Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
    Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
    Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
    Li H; Liu ZQ; Ding J; Chen YH
    Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies from HIV-positive and AIDS patients bind to an HIV envelope multivalent vaccine.
    Carlos MP; Yamamura Y; Díaz-Mitoma F; Torres JV
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):317-24. PubMed ID: 10634192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development.
    Putney SD; Rusche J; Javaherian K; Matthews T; Bolognesi D
    Biotechnology; 1990; 14():81-110. PubMed ID: 1691670
    [No Abstract]   [Full Text] [Related]  

  • 8. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
    Neurath AR; Strick N
    Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV.
    Mitchell WM; Ding L; Gabriel J
    AIDS; 1998 Jan; 12(2):147-56. PubMed ID: 9468363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
    Stephens DM; Eichberg JW; Haigwood NL; Steimer KS; Davis D; Lachmann PJ
    J Gen Virol; 1992 May; 73 ( Pt 5)():1099-106. PubMed ID: 1375277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 14. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
    Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
    EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
    Dong XN; Chen YH
    Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.